Halozyme Therapeutics (HALO) Change in Receivables (2010 - 2026)

Halozyme Therapeutics (HALO) has 17 years of Change in Receivables data on file, last reported at $19.5 million in Q1 2026.

• On a quarterly basis, Change in Receivables rose 609.83% year-over-year to $19.5 million in Q1 2026; TTM through Mar 2026 was $151.4 million, a 39.3% increase from a year earlier, with the FY2025 full-year figure at $128.1 million, up 72.49% from the prior year.
• Change in Receivables for Q1 2026 stood at $19.5 million, down from $90.5 million in the prior quarter.
• Over the last five years, Change in Receivables for HALO reached as high as $90.5 million in Q4 2025 and fell as low as -$38.3 million in Q1 2024.
• Historically, Change in Receivables has averaged $18.2 million across 5 years, with a median of $18.6 million in 2024.
• Across the five-year window, Change in Receivables slumped 258.81% in 2023 and soared 609.83% in 2026, its largest moves.
• Year by year, Change in Receivables stood at $7.8 million in 2022, then surged by 117.73% to $16.9 million in 2023, then surged by 34.51% to $22.7 million in 2024, then jumped by 298.39% to $90.5 million in 2025, then slumped by 78.4% to $19.5 million in 2026.
• Per Business Quant data, the three most recent Change in Receivables figures were $19.5 million in Q1 2026, $90.5 million in Q4 2025, and $29.7 million in Q3 2025.